Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Published on October 15, 2012 at 12:14 PM · No Comments

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City. Martin Freed, MD, Chief Medical Officer and co-founder of Civitas, will present the CVT-301 Phase 1 study results. CVT-301 is an inhaled levodopa (L-dopa) formulation, being developed to provide rapid alleviation of intermittent motor fluctuations ("off" episodes) associated with Parkinson's disease.

“By enabling patients to rapidly and consistently increase their L-dopa plasma levels as they sense 'off' symptoms, CVT-301 has the potential to dramatically improve their ability to reliably manage their symptoms and regain control of their daily lives.”

"While L-dopa remains the most effective and widely used symptomatic agent for Parkinson's disease, the significant intrinsic variability of the conventional oral administration of L-dopa contributes to unpredictable 'off' episodes that have a devastating impact on patients' lives," said Dr. Freed. "By enabling patients to rapidly and consistently increase their L-dopa plasma levels as they sense 'off' symptoms, CVT-301 has the potential to dramatically improve their ability to reliably manage their symptoms and regain control of their daily lives."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post